Press release
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative Therapies In The HER2-Positive Breast Cancer Market
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period?
Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth rate (CAGR) of 7.34%. Considerable factors contributing to this growth during the historic period include the surge in early detection and diagnosis, heightened knowledge of HER2-positive types, increased funding for research and development, growing acceptance of precision medicine, and an intensified focus on elevating patient outcomes.
The market size for HER2-positive breast cancer treatment is projected to experience robust growth in the upcoming years, escalating to $14.41 billion in 2029 with a compound annual growth rate (CAGR) of 7.08%. Factors driving this growth in the forecasted period include increased demand for liquid biopsy used for non-invasive monitoring, enhanced adoption of combined treatments, a heightened focus on immunotherapies and new drug formulations, increased application of liquid biopsy techniques for non-invasive monitoring, and rising number of specialized cancer treatment facilities. Key trends in the anticipated period include advancements in focused therapies, novel formulations, innovative immunotherapy methods, development of new HER2-targeted treatments, and advances in biomarkers facilitating improved patient stratification.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20832
What Are the High-Growth Segments in the HER2-Positive Breast Cancer Market?
The HER2-positive breast cancer market covered in this report is segmented -
1) By Treatment Type: Targeted Therapy, Chemotherapy, Endocrine Therapy, Immunotherapy, Other Treatment Types
2) By Route Of Administration: Parenteral, Oral, Other Route Of Administrations
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End User
Subsegments:
1) By Targeted Therapy: HER2 Inhibitors (Trastuzumab, Pertuzumab), Tyrosine Kinase Inhibitors (TKIs), Antibody-Drug Conjugates (ADC), Small Molecule Inhibitors
2) By Chemotherapy: Anthracycline-based Chemotherapy, Taxane-based Chemotherapy, Platinum-based Chemotherapy, Combination Chemotherapy Regimens
3) By Endocrine Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Estrogen Receptor Antagonists, Estrogen Deprivation Therapy
4) By Immunotherapy: Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors), Monoclonal Antibodies for Immune Modulation, Cancer Vaccines
5) By Other Treatment Types: Radiation Therapy, Stem Cell Therapy, Hyperthermia Treatment, Gene Therapy, Surgical Interventions (Mastectomy, Breast Conserving Surgery)
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20832&type=smp
What Key Drivers Are Expected to Influence Future HER2-Positive Breast Cancer Market Growth?
The growth of the HER2-positive breast cancer market is expected to be propelled by the robust acceptance of immunotherapy treatments. Immunotherapy is a medical practice that augments or alters the immune system's natural disease-fighting ability encompassing cancer, infections, and autoimmune diseases. The rise in immunotherapy use can be attributed to its enhanced performance in identifying and destroying cancer cells, providing greater efficacy with fewer side effects than traditional treatments. It benefits HER2-positive breast cancer by boosting the body's immune defenses to detect and combat cancer cells ere*xpressing HER2, improving treatment's effectiveness and reducing reoccurrence chances. For example, in July 2023, as per data released by the American Association for Cancer Research, a US organization, the FDA approved 11 immune checkpoint inhibitors (ICIs) in 2023, with at least one ICI approved for treating 20 varied cancer types and any solid tumor showing specific molecular traits. Thus, the robust acceptance of immunotherapy is spurring the growth of the HER2-positive breast cancer market.
Which Companies Hold the Largest Share Across Different HER2-Positive Breast Cancer Market Segments?
Major companies operating in the HER2-positive breast cancer market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis International AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim GmbH, Daiichi Sankyo Co. Ltd., Incyte Corporation, BioNTech SE, MacroGenics Inc., CStone Pharmaceuticals Co. Ltd., Sorrento Therapeutics Inc., Syndax Pharmaceuticals Inc., Fate Therapeutics Inc., Ambrx Biopharma Inc.
What Trends Are Driving Growth in The Acute Hospital Care Market?
The key focus of prominent companies in the HER2-positive breast cancer market is the development of groundbreaking therapies, such as HER2-directed antibody-drug conjugates (ADCs), aiming to simplify and better the patient treatment process. HER2-directed antibody-drug conjugates (ADCs) are cancer treatments that fuse an HER2-specific antibody with a cytotoxic drug, administering the drug straight to HER2-positive cancer cells thus making the treatment more efficacious. For example, in January 2024, Trastuzumab deruxtecan, a novel therapy, was introduced by AstraZeneca India Pharma Ltd., which is a biopharmaceutical firm based in India. The therapy, which is a HER2-directed antibody-drug conjugate (ADC) capable of delivering a cytotoxic drug straight to HER2 positive cancer cells, provides a more precise and effective treatment for patients. This therapy was devised via a partnership between AstraZeneca and Daiichi Sankyo.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/her2-positive-breast-cancer-global-market-report
What Are the Emerging Geographies for The HER2-Positive Breast Cancer Market Growth?
North America was the largest region in the HER2- positive breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the HER2-positive breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the HER2-Positive Breast Cancer Market?
2. What is the CAGR expected in the HER2-Positive Breast Cancer Market?
3. What Are the Key Innovations Transforming the HER2-Positive Breast Cancer Industry?
4. Which Region Is Leading the HER2-Positive Breast Cancer Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative Therapies In The HER2-Positive Breast Cancer Market here
News-ID: 4067288 • Views: …
More Releases from The Business Research Company

Furniture Foam Market: Major Trends Reshaping the Future of the Industry
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Furniture Foam Industry Market Size Be by 2025?
Recent years have seen a significant increase in the furniture foam market, with its size projected to rise from $58.61 billion in 2024 to $62.27 billion in 2025. This represents a compound annual growth rate (CAGR) of 6.2%.…

Awareness About The Importance Of A Healthy Diet Drives The Growth In The Fruit …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Fruit Cultivation Market Through 2025?
The market size for fruit cultivation has seen significant expansion in the recent past. The projection is that it will expand from $5.77 billion in 2024 to reach $6.22 billion in 2025, representing a compound annual growth…

Growth in Food Courts and Malls Drives Food Services And Drinking Places Market: …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Food Services And Drinking Places Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for food services and drinking establishments has seen a significant expansion in the recent past. The projections indicate that it will escalate from a worth of $2684.74 billion in…

Future of the Foliar Fertilizer Market: Trends, Innovations, and Key Forecasts T …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Foliar Fertilizer Market Size Growth Forecast: What to Expect by 2025?
The market size for foliar fertilizer has experienced robust growth in the past few years. The market, which stood at $11.04 billion in 2024, is projected to increase to $11.74 billion in 2025 with a compound annual growth…
More Releases for HER2
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze…
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
HER2 negative Breast Cancer Pipeline involves 85+ key companies continuously wor …
DelveInsight's HER2 negative Breast Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the HER2 negative Breast Cancer pipeline domain.
Some of the essential takeaways from the HER2 negative Breast Cancer Pipeline report:
• DelveInsight's HER2 negative Breast Cancer Pipeline analysis depicts a robust space with…
Her2 Antibodies Market: Industry Overview and Key Factors
Global Her2 Antibodies Market: Overview
Human epidermal growth factor receptor 2 (Her2) refers to an oncogene whose over-expression or amplification is commonly associated with the development of an aggressive type of breast cancer. Patients having the over-expression of Her2 receptors are diagnosed with the help of tests such as Fluorescent In-Situ Hybridization (FISH) and Immunohistochemistry (IHC).
The American Cancer Society states that around 15-30% of breast cancer cases over-express the Her2…